Tag: GlobeNewswire

Former NYPD Deputy Commissioner Edward Delatorre Jr. brings 46 years of law enforcement leadership and proven experience turning lifesaving interventions into department-wide operational capabilities

MIAMI, Nov. 02, 2026 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (NASDAQ: WRAP) (“WRAP” or the “Company”), a provider of non-lethal response technologies and public safety solutions, today announced the appointment of former New York City Police Department Deputy Commissioner Edward Delatorre Jr. to its Board of Directors, effective October 20, 2026.

Delatorre brings more than four decades of law enforcement leadership and a particularly relevant achievement: helping introduce Narcan into NYPD patrol operations, demonstrating how a lifesaving intervention could move from a local pilot to citywide adoption.

Now, WRAP is looking to apply lessons from that experience to a new challenge: operationalizing de-escalation.

From Emergency Medical Intervention to Proactive De-Escalation

While commanding NYPD Patrol Borough Staten Island, Delatorre worked alongside community organizations, elected officials, and public safety stakeholders to develop and launch a program training and equipping police officers with Narcan, a medication capable of reversing opioid overdoses.

The initiative was subsequently adopted citywide, helping establish Narcan as an additional emergency response capability for NYPD officers.

The significance extended beyond the medication itself. Its implementation required agency leadership, standardized training, operational policy, and institutional acceptance.

“Under my command, Ed Delatorre demonstrated the kind of leadership it takes to turn a promising idea into meaningful, lasting change. He helped take the NYPD’s Narcan program from a local pilot to citywide implementation, and I later sent him to the Police Executive Research Forum (PERF) to help other departments adopt similar programs. What began locally became a model shared nationally and internationally, reflecting Ed’s ability to bring people together, turn ideas into practice, and share lessons that could benefit communities far beyond New York,” said William J. Bratton, Former NYPD Police Commissioner.

WRAP sees an important parallel in its mission to make non-lethal response technologies, including BolaWrap®, practical and sustainable capabilities for law enforcement agencies.

Just as Narcan expanded what officers could do when encountering a life-threatening medical emergency, BolaWrap is designed to provide officers with an additional intervention option during certain encounters, potentially reducing the need for more injurious force.

The common principle is early intervention: equipping officers with additional tools, training, and clearly defined procedures to protect lives before emergencies escalate.

Operationalizing De-Escalation: Beyond the Device

WRAP’s strategy extends beyond equipment sales to an integrated approach combining non-lethal technology, constitutional policing principles, agency policy, instructor development, digital learning, and operational readiness.

Delatorre’s experience provides a valuable perspective on how agencies evaluate, introduce, train on, and ultimately institutionalize new response capabilities.

“With the launch of our operationalized de-escalation program, WRAP is finally in a position to support major cities with an integrated approach that brings together policy, training, and non-lethal technology,” said Scot Cohen, Chief Executive Officer of WRAP. “Ed understands what it takes to put new capabilities into practice at scale. His experience will be invaluable as we help departments give officers more options to resolve difficult encounters while protecting the people on both sides of the badge.”

A Career Built on Turning Innovation into Operational Practice

During his 46-year NYPD career, Delatorre served as Deputy Commissioner of Labor Relations, Chief of Transit, Commanding Officer of Patrol Borough Staten Island, and Commanding Officer of the NYPD Police Academy.

As Chief of Transit, he oversaw approximately 2,600 uniformed officers, secured nearly $40 million in federal counterterrorism grants, and helped establish an agreement with federal authorities to use the New York City transit system as a testing environment for emerging security technologies.

His experience leading the Police Academy provides additional expertise in the institutional requirements of training, certification, instructor development, and sustained readiness.

“Throughout my career, I’ve seen how much preparation goes into giving officers an option they can confidently use in the field,” said Delatorre. “Equipment, policy, training, and leadership all have to work together. I look forward to bringing that perspective to WRAP’s Board and supporting the Company’s work to help agencies prepare their officers for difficult encounters.”

The Next Chapter in First Responder Readiness

WRAP believes the historical adoption of Narcan offers a valuable lesson for the future of law enforcement innovation: a new technology achieves its greatest potential when it becomes part of an agency’s established operational framework.

Through its BolaWrap technology, Non-Lethal Response™ strategy, and expanding training infrastructure, WRAP is working to provide agencies with additional options intended to support earlier intervention, better decision-making, and improved public safety outcomes.

Delatorre’s appointment brings experience navigating the institutional challenges of introducing new capabilities into one of the world’s largest police departments.

The opportunity is not simply to introduce another device into policing. It is to help make lawful, proactive de-escalation a trained, repeatable, and operationally supported capability.

About Wrap Technologies, Inc.

Wrap Technologies, Inc. (NASDAQ: WRAP) is a public safety technology company focused on non-lethal response solutions, training, and integrated technologies designed to support law enforcement and security professionals. Through its BolaWrap® family of remote restraint devices, training programs, and expanding technology portfolio, WRAP seeks to provide officers and agencies with additional options to manage encounters, support de-escalation, and improve public safety outcomes. For more information, visit www.wrap.com.

Trademark Information

WRAP, the Wrap logo, BolaWrap®, Non-Lethal Response™, WrapReality™, and Wrap Training Academy are trademarks of WRAP Technologies, Inc., some of which are registered in the U.S. and abroad. All other trade names used herein are either trademarks or registered trademarks of their respective holders.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements include, among others, statements regarding the expected contributions, perspective, and value that Mr. Delatorre’s experience and appointment may bring to the Company’s Board of Directors; the Company’s Non-Lethal Response™ strategy and its approach of combining policy, training, and technology to support officer judgment and expand response options; the Company’s ability to make its capabilities practical for agencies to adopt and sustain; and the anticipated adoption of WRAP’s products, training, and technologies by law enforcement and public safety agencies. These statements are based on current expectations and assumptions and are subject to risks and uncertainties, including but not limited to the pace of customer and agency adoption; changes in law enforcement budgets, policies, procurement practices, and use-of-force standards; the availability and terms of technology and training partnerships; regulatory developments; competitive conditions; the Company’s ability to attract and retain qualified personnel and directors; and the Company’s ability to develop, manufacture, sell, and support its products and training solutions. Actual results could differ materially from those expressed or implied. WRAP undertakes no obligation to update or revise any forward-looking statement, and investors are cautioned not to place undue reliance on them.

Investor Relations Contact
(800) 583-2652 | ir@wrap.com

Repeat orders underscore continued customer commitment as DefendAir advances through vehicle integration toward planned demonstrations for European end users and senior NATO military officers, expected by the end of 2026

Kfar Saba, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “Company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced that it has received a fourth order for DefendAir Net Pods from a Tier-1 European defense company. The order follows the successful completion of initial integration work and a live demonstration conducted on the customer’s own armored vehicle at its test facility in Europe.

Conducted at the customer’s test facility, the demonstration included the sequential neutralization of multiple drone threats using DefendAir installed on the customer’s armored vehicle. The platform configuration, weather conditions and threat scenarios were selected to reflect realistic operating conditions, providing a practical test of the technology within the customer’s protection architecture.

The customer subsequently placed its fourth order to support continued integration work and planned demonstrations for European end users. This fourth order builds on the collaboration established under the parties’ September 2026 Memorandum of Understanding to develop a vehicle-integrated active protection capability against attack drones.

ParaZero expects the integration program to be completed by the end of 2026 through an extensive series of trials at the customer’s facility designed to simulate combat conditions. During this period, the Company also expects multiple demonstrations to be held for senior military officers from NATO member states.

“We believe the progression from initial integration to a fourth order, combined with a successful demonstration on the customer’s own armored vehicle under realistic multi-threat conditions, demonstrates both the operational relevance of DefendAir and the strength of this collaboration,” said Ariel Alon, Chief Executive Officer of ParaZero. “By year-end, we expect to complete the integration through rigorous testing designed to simulate combat conditions and to present the capability to senior military officers from NATO member states, which we believe will reinforce DefendAir’s position as a practical, non-explosive physical interception layer for next-generation armored platforms.”

DefendAir’s modular Net Pod architecture is designed for integration into vehicle-mounted, autonomous, remotely operated and fixed Counter-UAS systems. The system provides defense manufacturers and platform integrators with a controlled, non-explosive, net-based physical interception component that can be incorporated into broader protection architectures according to the platform, threat profile and operational environment.

About ParaZero Technologies

ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry.

Founded in 2014 by aviation professionals and drone industry veterans, ParaZero develops intelligent, mission-ready technologies for defense and advanced aerial applications.

The Company’s DefendAir product family provides a controlled, non-explosive, net-based physical interception capability designed for integration across personal, mobile, autonomous and fixed-site Counter-UAS systems.

For more information, visit ParaZero https://parazero.com/

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding ParaZero’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected completion of the integration program by the end of 2026; planned trials and demonstrations of DefendAir for European end users and senior military officers from NATO member states; and the potential for such activities to reinforce DefendAir’s position as a practical, non-explosive physical interception layer for next-generation armored platforms. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 26, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

Repeat orders underscore continued customer commitment as DefendAir advances through vehicle integration toward planned demonstrations for European end users and senior NATO military officers, expected by the end of 2026

Kfar Saba, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “Company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced that it has received a fourth order for DefendAir Net Pods from a Tier-1 European defense company. The order follows the successful completion of initial integration work and a live demonstration conducted on the customer’s own armored vehicle at its test facility in Europe.

Conducted at the customer’s test facility, the demonstration included the sequential neutralization of multiple drone threats using DefendAir installed on the customer’s armored vehicle. The platform configuration, weather conditions and threat scenarios were selected to reflect realistic operating conditions, providing a practical test of the technology within the customer’s protection architecture.

The customer subsequently placed its fourth order to support continued integration work and planned demonstrations for European end users. This fourth order builds on the collaboration established under the parties’ September 2026 Memorandum of Understanding to develop a vehicle-integrated active protection capability against attack drones.

ParaZero expects the integration program to be completed by the end of 2026 through an extensive series of trials at the customer’s facility designed to simulate combat conditions. During this period, the Company also expects multiple demonstrations to be held for senior military officers from NATO member states.

“We believe the progression from initial integration to a fourth order, combined with a successful demonstration on the customer’s own armored vehicle under realistic multi-threat conditions, demonstrates both the operational relevance of DefendAir and the strength of this collaboration,” said Ariel Alon, Chief Executive Officer of ParaZero. “By year-end, we expect to complete the integration through rigorous testing designed to simulate combat conditions and to present the capability to senior military officers from NATO member states, which we believe will reinforce DefendAir’s position as a practical, non-explosive physical interception layer for next-generation armored platforms.”

DefendAir’s modular Net Pod architecture is designed for integration into vehicle-mounted, autonomous, remotely operated and fixed Counter-UAS systems. The system provides defense manufacturers and platform integrators with a controlled, non-explosive, net-based physical interception component that can be incorporated into broader protection architectures according to the platform, threat profile and operational environment.

About ParaZero Technologies

ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry.

Founded in 2014 by aviation professionals and drone industry veterans, ParaZero develops intelligent, mission-ready technologies for defense and advanced aerial applications.

The Company’s DefendAir product family provides a controlled, non-explosive, net-based physical interception capability designed for integration across personal, mobile, autonomous and fixed-site Counter-UAS systems.

For more information, visit ParaZero https://parazero.com/

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding ParaZero’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected completion of the integration program by the end of 2026; planned trials and demonstrations of DefendAir for European end users and senior military officers from NATO member states; and the potential for such activities to reinforce DefendAir’s position as a practical, non-explosive physical interception layer for next-generation armored platforms. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 26, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

WINTER PARK, Fla., Nov. 02, 2026 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”), an owner and operator of single-tenant net leased commercial income properties, today announced that it has completed the acquisition of the previously announced 13-property industrial portfolio for $117.3 million, or $63 per square foot. The portfolio totals approximately 1.9 million square feet across 209 acres in 11 states and is 100% leased to nine tenants under absolute triple-net leases.

“With 10.2 years of weighted average remaining lease term and annual rent escalators built into the leases, this portfolio of mission-critical manufacturing and distribution facilities delivers an attractive initial yield with future cash flow growth,” said John P. Albright, President and Chief Executive Officer of Alpine Income Property Trust.

The Company funded the acquisition with borrowings under its revolving credit facility.

About Alpine Income Property Trust, Inc. 

Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased commercial income properties that are predominately leased to high-quality publicly traded and credit-rated tenants. The Company also complements its income property portfolio by strategically investing in a select portfolio of commercial loan investments intended to deliver an attractive risk-adjusted return.

We encourage you to review our most recent investor presentation which is available on our website at http://www.alpinereit.com.  

Safe Harbor 

This press release may contain “forward-looking statements.” Forward-looking statements include statements that may be identified by words such as “potential,” “outlook,” “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections. Statements, among others, relating to the anticipated benefits of the Company’s acquisition of the industrial portfolio and potential future cash flow growth are forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions regarding capital market conditions, the Company’s business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include general business and economic conditions, continued volatility and uncertainty in the credit markets and broader financial markets, geopolitical conflicts, tariffs and international trade policies, risks inherent in the real estate business, including tenant or borrower defaults, potential liability relating to environmental matters, credit risk associated with the Company investing in commercial loans and investments, illiquidity of real estate investments and potential damages from natural disasters, the impact of epidemics or pandemics on the Company’s business and the businesses of its tenants and borrowers and the impact of such epidemics or pandemics on the U.S. economy and market conditions generally, other factors affecting the Company’s business or the businesses of its tenants and borrowers that are beyond the control of the Company or its tenants or borrowers, and the factors set forth under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other risks and uncertainties discussed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

CONTACT: Contact:
Investor Relations
ir@alpinereit.com

WINTER PARK, Fla., Nov. 02, 2026 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”), an owner and operator of single-tenant net leased commercial income properties, today announced that it has completed the acquisition of the previously announced 13-property industrial portfolio for $117.3 million, or $63 per square foot. The portfolio totals approximately 1.9 million square feet across 209 acres in 11 states and is 100% leased to nine tenants under absolute triple-net leases.

“With 10.2 years of weighted average remaining lease term and annual rent escalators built into the leases, this portfolio of mission-critical manufacturing and distribution facilities delivers an attractive initial yield with future cash flow growth,” said John P. Albright, President and Chief Executive Officer of Alpine Income Property Trust.

The Company funded the acquisition with borrowings under its revolving credit facility.

About Alpine Income Property Trust, Inc. 

Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased commercial income properties that are predominately leased to high-quality publicly traded and credit-rated tenants. The Company also complements its income property portfolio by strategically investing in a select portfolio of commercial loan investments intended to deliver an attractive risk-adjusted return.

We encourage you to review our most recent investor presentation which is available on our website at http://www.alpinereit.com.  

Safe Harbor 

This press release may contain “forward-looking statements.” Forward-looking statements include statements that may be identified by words such as “potential,” “outlook,” “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections. Statements, among others, relating to the anticipated benefits of the Company’s acquisition of the industrial portfolio and potential future cash flow growth are forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions regarding capital market conditions, the Company’s business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include general business and economic conditions, continued volatility and uncertainty in the credit markets and broader financial markets, geopolitical conflicts, tariffs and international trade policies, risks inherent in the real estate business, including tenant or borrower defaults, potential liability relating to environmental matters, credit risk associated with the Company investing in commercial loans and investments, illiquidity of real estate investments and potential damages from natural disasters, the impact of epidemics or pandemics on the Company’s business and the businesses of its tenants and borrowers and the impact of such epidemics or pandemics on the U.S. economy and market conditions generally, other factors affecting the Company’s business or the businesses of its tenants and borrowers that are beyond the control of the Company or its tenants or borrowers, and the factors set forth under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other risks and uncertainties discussed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

CONTACT: Contact:
Investor Relations
ir@alpinereit.com

Toronto, Ontario, Nov. 02, 2026 (GLOBE NEWSWIRE) — Fort Technology Inc. (Nasdaq: FRTT, TSXV: FORT) (“Fort” or the “Company”), today announced that the TSX Venture Exchange (“TSXV”) has approved the voluntary delisting of the Company’s common shares from the TSXV. The voluntary delisting from the TSXV will not affect the listing of the Company’s common shares on the Nasdaq Capital Market (the “Nasdaq”), which will continue to trade on the Nasdaq under the symbol FRTT.

The Company believes that the trading volume of its shares on the TSXV no longer justifies the expenses and administrative efforts required to maintain a dual listing. The Company also believes that delisting from the TSXV will create a central marketplace for its common shares on the Nasdaq, and ultimately benefit the long-term liquidity and shareholder value of the Company.

It is anticipated that, effective as at the close of trading on or about November 6, 2026, Fort’s common shares will no longer be listed and posted for trading on the TSXV.

Following delisting from the TSXV, Fort’s shareholders can trade their common shares through their brokers on Nasdaq. As most brokers in Canada, including many discount and online brokers, have the ability to buy and sell securities listed on Nasdaq, Fort’s Nasdaq listing will continue to provide shareholders with accessibility to trade the Company’s common shares. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade Fort’s shares on the NASDAQ.

About Fort Technology

Fort is engaged in the retail sale of consumer products, primarily serving the pest control and remedial repair industries. Fort develops, markets and sells a range of products for both amateur and professional customers under its proprietary brands, including Roshield, Entopest, Rempro and BirdGo. Products are sold primarily through Amazon marketplaces in the United Kingdom and Europe as well as through other online sales channels. Fort currently serves customers throughout the United Kingdom and continental Europe and plans to expand its retail operations into the United States, subject to applicable regulatory approvals, including through the acquisition of Logia USA Inc., a company focused on selling advanced fuel integrity solutions for data centers and other mission-critical facilities in the United States.

For further information, please contact:

Gabi Kabazo
Chief Executive Officer
Fort Technology Inc.
Telephone: (604) 833-6820
Email: Office@Fort-Tech.io

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Fort intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be about future events, including statements regarding the anticipated timing of the delisting, the expected effects of the delisting, including the creation of a central marketplace for the Company’s common shares, and the potential effects of the delisting on liquidity and shareholder value, and statements regarding Fort’s intentions, objectives, plans, expectations, assumptions and beliefs about future events, including Fort’s expectations with respect to the financial and operating performance of its business, its capital position, and future growth. The words “anticipate”, “believe”, “expect”, “project”, “predict”, “will”, “forecast”, “estimate”, “likely”, “intend”, “outlook”, “should”, “could”, “may”, “target”, “plan” and other similar expressions can generally be used to identify forward-looking statements. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43178), as amended, as filed with the SEC on May 1, 2026 or the Company’s publicly filed documents which are available on SEDAR+ at www.sedarplus.ca. All forward-looking statements contained in this press release speak only as of the date on which they were made. Fort undertakes no obligation to update such statements to reflect changes in assumptions or changes in events that occur or circumstances that exist after the date on which they were made other than as required by applicable laws, rules and regulations.

Toronto, Ontario, Nov. 02, 2026 (GLOBE NEWSWIRE) — Fort Technology Inc. (Nasdaq: FRTT, TSXV: FORT) (“Fort” or the “Company”), today announced that the TSX Venture Exchange (“TSXV”) has approved the voluntary delisting of the Company’s common shares from the TSXV. The voluntary delisting from the TSXV will not affect the listing of the Company’s common shares on the Nasdaq Capital Market (the “Nasdaq”), which will continue to trade on the Nasdaq under the symbol FRTT.

The Company believes that the trading volume of its shares on the TSXV no longer justifies the expenses and administrative efforts required to maintain a dual listing. The Company also believes that delisting from the TSXV will create a central marketplace for its common shares on the Nasdaq, and ultimately benefit the long-term liquidity and shareholder value of the Company.

It is anticipated that, effective as at the close of trading on or about November 6, 2026, Fort’s common shares will no longer be listed and posted for trading on the TSXV.

Following delisting from the TSXV, Fort’s shareholders can trade their common shares through their brokers on Nasdaq. As most brokers in Canada, including many discount and online brokers, have the ability to buy and sell securities listed on Nasdaq, Fort’s Nasdaq listing will continue to provide shareholders with accessibility to trade the Company’s common shares. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade Fort’s shares on the NASDAQ.

About Fort Technology

Fort is engaged in the retail sale of consumer products, primarily serving the pest control and remedial repair industries. Fort develops, markets and sells a range of products for both amateur and professional customers under its proprietary brands, including Roshield, Entopest, Rempro and BirdGo. Products are sold primarily through Amazon marketplaces in the United Kingdom and Europe as well as through other online sales channels. Fort currently serves customers throughout the United Kingdom and continental Europe and plans to expand its retail operations into the United States, subject to applicable regulatory approvals, including through the acquisition of Logia USA Inc., a company focused on selling advanced fuel integrity solutions for data centers and other mission-critical facilities in the United States.

For further information, please contact:

Gabi Kabazo
Chief Executive Officer
Fort Technology Inc.
Telephone: (604) 833-6820
Email: Office@Fort-Tech.io

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Fort intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be about future events, including statements regarding the anticipated timing of the delisting, the expected effects of the delisting, including the creation of a central marketplace for the Company’s common shares, and the potential effects of the delisting on liquidity and shareholder value, and statements regarding Fort’s intentions, objectives, plans, expectations, assumptions and beliefs about future events, including Fort’s expectations with respect to the financial and operating performance of its business, its capital position, and future growth. The words “anticipate”, “believe”, “expect”, “project”, “predict”, “will”, “forecast”, “estimate”, “likely”, “intend”, “outlook”, “should”, “could”, “may”, “target”, “plan” and other similar expressions can generally be used to identify forward-looking statements. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43178), as amended, as filed with the SEC on May 1, 2026 or the Company’s publicly filed documents which are available on SEDAR+ at www.sedarplus.ca. All forward-looking statements contained in this press release speak only as of the date on which they were made. Fort undertakes no obligation to update such statements to reflect changes in assumptions or changes in events that occur or circumstances that exist after the date on which they were made other than as required by applicable laws, rules and regulations.

• ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX^®
• Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1) for infantile and epileptic spasms
• Research conducted at Baylor College of Medicine and Texas Children’s Hospital and funded by CURE Epilepsy and NIH, showed IGF-1 therapy led to reduction in spasms in the majority of treated animals
• An Investigational New Drug application (IND) has been submitted to the United States Food and Drug Administration (FDA) for an investigator-sponsored Phase 2 study to evaluate mecasermin/IGF-1 in children with refractory epileptic spasms, with first patient dosing planned in Q1 2027
• Eton retains commercial rights to ET-900 and the product candidate would align with the Company’s planned entry into the pediatric neurology therapeutic area

DEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced ET-900, a new development program evaluating mecasermin injection for the treatment of infantile and epileptic spasms. Mecasermin is a recombinant form of IGF-1 and the active ingredient in INCRELEX, which Eton markets in the United States. The Company has entered into a license agreement with Baylor College of Medicine covering patent rights related to the use of IGF-1 for the treatment of spasms.

“These spasms can have devastating and lifelong consequences for children and their families, and there remains a significant and urgent need for new therapeutic approaches due to high rates of resistance to current therapies,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals. “The Baylor research provides a compelling scientific rationale for evaluating IGF-1 therapy for use with this condition. With an IND now submitted, we are excited to help translate this research into meaningful clinical advancement.”

Research led by Dr. John W. Swann, Ph.D., Distinguished Emeritus Professor of Pediatrics and Neuroscience at Baylor College of Medicine, and funded by CURE Epilepsy has identified impaired IGF-1 signaling as a potential contributor to the development of epileptic spasms. In an animal model, treatment with recombinant human IGF-1 reduced daily spasm counts by approximately 50% and eliminated spasms in 20% of treated animals. These preclinical findings provide a scientific rationale for evaluating mecasermin in children with refractory epileptic spasms.

“The planned clinical trial is also warranted because studies of spasms patients with structural brain abnormalities indicate that IGF-1 levels are reduced in their brains. Consequently, we hope that mecasermin/IGF-1 will serve as a replacement therapy to restore normal brain activity,” added Dr. Swann.  

“CURE Epilepsy is thrilled to see this long-standing line of research from Dr. Swann’s lab move into human clinical trials. Dr. Swann was part of our Infantile Spasms Initiative, which began in 2012, and he and his collaborators have continued to fight to move their basic science discoveries toward clinical relevance for patients and families. Pediatric refractory epileptic spasms are catastrophic; these children urgently need new and better options, and we are grateful to Eton Pharmaceuticals for sponsoring this important next step towards a potential new treatment,” said Beth Dean, CEO of CURE Epilepsy.

A research IND has been submitted for an investigator-sponsored Phase 2 to evaluate mecasermin for efficacy, safety, and tolerability in children with refractory epileptic spasms. The study will be sponsored by the University of Chicago and is expected to enroll up to 20 patients ages 2–18 years across three sites, University of Chicago, Baylor College of Medicine, and UCLA, whose spasms have not responded to, or who have been unable to tolerate, hormonal therapy and vigabatrin. Patients will receive twice-daily subcutaneous injections during an initial three- to five-week treatment period. An additional treatment course may be available to certain patients based on clinical response. The study will assess spasm resolution, changes in daily spasm frequency, and resolution or improvement of associated electroencephalogram (“EEG”) abnormalities. Additional assessments will evaluate safety, tolerability, and adaptive functioning. Mecasermin is not FDA-approved for the treatment of infantile or epileptic spasms, and its safety and efficacy for these uses have not been established. Initial enrollment and dosing are targeted for the first quarter of 2027.

About Infantile and Epileptic Spasms

Infantile epileptic spasms syndrome is a rare, severe form of epilepsy that typically begins between the ages of 1 and 24 months. According to the American Academy of Pediatrics, approximately 2,500 children are diagnosed with infantile spasms in the United States each year. When spasms persist beyond the age of 2 they are referred to as epileptic spasms.

These seizures, known as epileptic spasms, frequently occur in clusters and may be accompanied by hypsarhythmia, a highly abnormal pattern of brain activity detected on an EEG. Spasms can persist beyond age two into later childhood. Prompt diagnosis and treatment are critical because persistent spasms may adversely affect neurological development.

Treatment resistance remains a significant challenge. A peer-reviewed study published in Epilepsy & Behavior reports that seizures in approximately half of children with infantile spasms fail to improve with initial treatment attempts. Current therapies are not effective for every patient and can be associated with significant limitations. For children whose spasms persist despite treatment, these challenges underscore an urgent need for new therapeutic options.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has twelve rare disease products: KHINDIVI^® (hydrocortisone), INCRELEX^® (mecasermin), ALKINDI SPRINKLE^® (hydrocortisone), DESMODA^™ (desmopressin acetate), GALZIN^® (zinc acetate), HEMANGEOL^® (propranolol hydrochloride), PKU GOLIKE^®, IMPAVIDO^® (miltefosine), LIBERVANT^® (diazepam), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: AMGLIDIA^® (glyburide oral suspension), ASN-001, ET-700, ET-800, ET-900, and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

• ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX^®
• Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1) for infantile and epileptic spasms
• Research conducted at Baylor College of Medicine and Texas Children’s Hospital and funded by CURE Epilepsy and NIH, showed IGF-1 therapy led to reduction in spasms in the majority of treated animals
• An Investigational New Drug application (IND) has been submitted to the United States Food and Drug Administration (FDA) for an investigator-sponsored Phase 2 study to evaluate mecasermin/IGF-1 in children with refractory epileptic spasms, with first patient dosing planned in Q1 2027
• Eton retains commercial rights to ET-900 and the product candidate would align with the Company’s planned entry into the pediatric neurology therapeutic area

DEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced ET-900, a new development program evaluating mecasermin injection for the treatment of infantile and epileptic spasms. Mecasermin is a recombinant form of IGF-1 and the active ingredient in INCRELEX, which Eton markets in the United States. The Company has entered into a license agreement with Baylor College of Medicine covering patent rights related to the use of IGF-1 for the treatment of spasms.

“These spasms can have devastating and lifelong consequences for children and their families, and there remains a significant and urgent need for new therapeutic approaches due to high rates of resistance to current therapies,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals. “The Baylor research provides a compelling scientific rationale for evaluating IGF-1 therapy for use with this condition. With an IND now submitted, we are excited to help translate this research into meaningful clinical advancement.”

Research led by Dr. John W. Swann, Ph.D., Distinguished Emeritus Professor of Pediatrics and Neuroscience at Baylor College of Medicine, and funded by CURE Epilepsy has identified impaired IGF-1 signaling as a potential contributor to the development of epileptic spasms. In an animal model, treatment with recombinant human IGF-1 reduced daily spasm counts by approximately 50% and eliminated spasms in 20% of treated animals. These preclinical findings provide a scientific rationale for evaluating mecasermin in children with refractory epileptic spasms.

“The planned clinical trial is also warranted because studies of spasms patients with structural brain abnormalities indicate that IGF-1 levels are reduced in their brains. Consequently, we hope that mecasermin/IGF-1 will serve as a replacement therapy to restore normal brain activity,” added Dr. Swann.  

“CURE Epilepsy is thrilled to see this long-standing line of research from Dr. Swann’s lab move into human clinical trials. Dr. Swann was part of our Infantile Spasms Initiative, which began in 2012, and he and his collaborators have continued to fight to move their basic science discoveries toward clinical relevance for patients and families. Pediatric refractory epileptic spasms are catastrophic; these children urgently need new and better options, and we are grateful to Eton Pharmaceuticals for sponsoring this important next step towards a potential new treatment,” said Beth Dean, CEO of CURE Epilepsy.

A research IND has been submitted for an investigator-sponsored Phase 2 to evaluate mecasermin for efficacy, safety, and tolerability in children with refractory epileptic spasms. The study will be sponsored by the University of Chicago and is expected to enroll up to 20 patients ages 2–18 years across three sites, University of Chicago, Baylor College of Medicine, and UCLA, whose spasms have not responded to, or who have been unable to tolerate, hormonal therapy and vigabatrin. Patients will receive twice-daily subcutaneous injections during an initial three- to five-week treatment period. An additional treatment course may be available to certain patients based on clinical response. The study will assess spasm resolution, changes in daily spasm frequency, and resolution or improvement of associated electroencephalogram (“EEG”) abnormalities. Additional assessments will evaluate safety, tolerability, and adaptive functioning. Mecasermin is not FDA-approved for the treatment of infantile or epileptic spasms, and its safety and efficacy for these uses have not been established. Initial enrollment and dosing are targeted for the first quarter of 2027.

About Infantile and Epileptic Spasms

Infantile epileptic spasms syndrome is a rare, severe form of epilepsy that typically begins between the ages of 1 and 24 months. According to the American Academy of Pediatrics, approximately 2,500 children are diagnosed with infantile spasms in the United States each year. When spasms persist beyond the age of 2 they are referred to as epileptic spasms.

These seizures, known as epileptic spasms, frequently occur in clusters and may be accompanied by hypsarhythmia, a highly abnormal pattern of brain activity detected on an EEG. Spasms can persist beyond age two into later childhood. Prompt diagnosis and treatment are critical because persistent spasms may adversely affect neurological development.

Treatment resistance remains a significant challenge. A peer-reviewed study published in Epilepsy & Behavior reports that seizures in approximately half of children with infantile spasms fail to improve with initial treatment attempts. Current therapies are not effective for every patient and can be associated with significant limitations. For children whose spasms persist despite treatment, these challenges underscore an urgent need for new therapeutic options.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has twelve rare disease products: KHINDIVI^® (hydrocortisone), INCRELEX^® (mecasermin), ALKINDI SPRINKLE^® (hydrocortisone), DESMODA^™ (desmopressin acetate), GALZIN^® (zinc acetate), HEMANGEOL^® (propranolol hydrochloride), PKU GOLIKE^®, IMPAVIDO^® (miltefosine), LIBERVANT^® (diazepam), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: AMGLIDIA^® (glyburide oral suspension), ASN-001, ET-700, ET-800, ET-900, and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

WATERLOO, Ontario and ATLANTA, Nov. 02, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX: DSG) (Nasdaq: DSGX), the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its third-quarter fiscal 2027 financial results after market close on Wednesday, December 2, 2026.

Members of Descartes’ executive management team will host a conference call to discuss the company’s financial results at 5:30 p.m. ET on Wednesday, December 2, 2026. Designated numbers are +1 289 514 5100 or Toll-Free for North America at +1 800 717 1738, using conference ID 32904.

The company will simultaneously conduct an audio webcast on the Descartes website at www.descartes.com/descartes/investor-relations. A phone conference dial-in or webcast log-in is required approximately 10 minutes before the start.

Replays of the conference call will be available until Wednesday, December 9, 2026, by dialing +1 289 819 1325 or Toll-Free for North America using +1 888 660 6264 with Playback Passcode: 32904#. An archived replay of the webcast will be available at www.descartes.com/descartes/investor-relations.

About Descartes

Descartes powers more responsive, efficient, secure, and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN, leveraging technology, data, and AI to manage last-mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance, and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Descartes Investor Contact
Laurie McCauley
(519) 746-2969
investor@descartes.com